4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001549595-24-000147
Chief Scientific Officer sold 3,437 shares at $24.31 ($83,536)
- Chief Scientific Officer acquired 8,957 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-10-30 | Exercise or conversion : show line 1 in the form | +3,207 | 48,357 | D | ||
| 2024-10-30 | Exercise or conversion : show line 2 in the form | +2,000 | 50,357 | D | ||
| 2024-10-30 | Exercise or conversion : show line 3 in the form | +3,750 | 54,107 | D | ||
| 2024-10-30 | Sale : show line 4 in the form | −3,437 | $24.31 | $83,536 | 50,670 | D |
| Open-market sales · 3,437 sh · avg $24.31 · $83,536 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-10-30 | Exercise or conversion : show line 5 in the form Restricted Stock Units | −3,207 | 16,034 | D |
| 2024-10-30 | Exercise or conversion : show line 6 in the form Restricted Stock Units | −2,000 | 12,000 | D |
| 2024-10-30 | Exercise or conversion : show line 7 in the form Restricted Stock Units | −3,750 | 37,500 | D |
Loading xslF345X05/wk-form4_1730334611.xml…